1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

Sandoz To Pump Another €50m Into Kundl Antibiotics Site

New Three-Floor Building For Penicillin FDFs Set To Open Early In 2024

 
• By Dean Rudge

To increase manufacturing capacity for finished dosage form penicillins, Sandoz is investing another €50m into its key antibiotics site in Kundl, Austria. But the company feels that fundamental reforms are needed from regulators to ensure the long-term sustainability of European-based antibiotic manufacturing and supply.

Euros (Izel Photography/Alamy Stock Photo)
Sandoz has committed hundreds of millions to its antibiotics operations • Source: Shutterstock (Izel Photography / Alamy Stock P/Alamy Stock Photo)

Designating itself previously as “pretty much now the only remaining vertically-integrated antibiotic manufacturer left in the western world,” Sandoz has announced plans to invest further at its manufacturing facility in Kundl, Austria, bringing total investment in the Sandoz antibiotics network across Europe to more than a quarter-of-a-billion euros.

The Novartis division will inject an additional €50m ($49

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

More from Business

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.